Terms Of Use | Privacy Policy



Early Detection: Diagnosis / Biomarkers


The positive impact of early detection on cancer mortality is one victory in the war on cancer; yet, there is enormous room for improving early detection / diagnosis of pancreatic, lung, and ovarian cancers. 

Those cancers typically are diagnosed in an advanced stage when chances of a cure are remote because there are no effective screening tests.

The focus of our early detection research is to develop improved early detection technologies and diagnostic biomarkers that can detect tumors at early stages. Thus, as an essential part of the CCPDD ongoing strategy, investigators are establishing early detection technologies by applying novel imaging biomarkers, circulating markers of solid tumors such as pancreatic, lung and ovarian cancers. 

Contact & Links


Contact Information

Center for Cancer Prevention and Drug Development Clinic
975 NE 10th St., BRC 1203
Oklahoma City, OK 73104
P: (405) 271-3224
F: (405) 271-3225


Chinthalapally V. Rao, PhD
View Profile


Collaborating Centers for NCI Prevention Cancer Drug / Biomarkers Development

Lombardi Cancer Center
MD Anderson Cancer Center
New York University Medical Center
Penn State Cancer Institute
Rutgers, the State University of New Jersey
The State University of New York, Stony Brook
University of Alabama
University of Alabama
University of Washington

Resources & Facilities

Various laboratories in the Center offer research experience and training opportunities to postdoctoral and clinical fellows, residents, and students ranging from high school through graduate levels.

Learn more about research and training opportunities >

Resources & Facilities